Profund Advisors LLC boosted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 9.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,490 shares of the company’s stock after buying an additional 918 shares during the period. Profund Advisors LLC’s holdings in Myriad Genetics were worth $321,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Lazard Asset Management LLC bought a new stake in Myriad Genetics during the second quarter valued at $54,000. AlphaCrest Capital Management LLC boosted its stake in Myriad Genetics by 234.1% during the second quarter. AlphaCrest Capital Management LLC now owns 36,786 shares of the company’s stock valued at $1,125,000 after buying an additional 25,775 shares during the period. Dimensional Fund Advisors LP boosted its stake in Myriad Genetics by 1.4% during the second quarter. Dimensional Fund Advisors LP now owns 2,768,704 shares of the company’s stock valued at $84,666,000 after buying an additional 37,825 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Myriad Genetics by 1.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 59,131 shares of the company’s stock valued at $1,808,000 after buying an additional 1,129 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Myriad Genetics by 182.8% during the second quarter. JPMorgan Chase & Co. now owns 793,332 shares of the company’s stock valued at $24,259,000 after buying an additional 512,766 shares during the period. 96.11% of the stock is owned by institutional investors.
In other Myriad Genetics news, Director Dennis Langer sold 30,000 shares of Myriad Genetics stock in a transaction dated Tuesday, August 3rd. The stock was sold at an average price of $34.75, for a total transaction of $1,042,500.00. Following the completion of the sale, the director now owns 119,527 shares of the company’s stock, valued at $4,153,563.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jerry S. Lanchbury sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 3rd. The shares were sold at an average price of $34.03, for a total value of $1,701,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 301,212 shares of company stock valued at $10,404,146. Corporate insiders own 1.70% of the company’s stock.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, August 3rd. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.21. Myriad Genetics had a negative return on equity of 4.29% and a negative net margin of 15.64%. The firm had revenue of $189.40 million during the quarter, compared to analyst estimates of $163.09 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue was up 103.2% compared to the same quarter last year. On average, equities analysts expect that Myriad Genetics, Inc. will post -0.42 earnings per share for the current fiscal year.
Myriad Genetics Company Profile
Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life.
Featured Story: Is it Safe to Invest in Commodities?
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.